NORWALK, Conn., Feb. 8, 2022 /PRNewswire/ -- TriRx Pharmaceutical
Services, LLC, a leading international CDMO, announced today that
it has finalized and closed on its agreement with Elanco Animal
Health Incorporated (NYSE:ELAN) to acquire the ownership and
operations of its manufacturing site in Speke, United Kingdom. Elanco is one of the world's
leading animal health companies, dedicated to innovating and
delivering products and services to prevent and treat disease in
farm animals and pets. The two companies agreed a two-facilty sale
and long-term supply agreement in 2021, covering a facility in
Shawnee, Kansas, USA, and the
Speke, UK site.
Timothy C. Tyson, Chairman &
CEO of TriRx, stated, "The Speke facility deal constitutes the
second part of our acquisition and supply agreement with Elanco,
following our closing on the Shawnee,
Kansas facility in August
2021. We look forward to continuing our successful strategic
partnership with this global leader. This important two-facility
acquisition represents a significant step in our strategy to be a
leading global CDMO in both animal health and human health. We
welcome the skilled workforce at Speke to TriRx, and look forward
to growing this team as we invest in the site, fulfilling the
long-term supply agreement with Elanco Animal Health and bringing
in new business as part of our strategic plan."
The Speke facility, initially built by Eli Lilly, offers
capabilities to manufacture human health and animal health
products. The sale includes the physical assets of the site and
transfer of approximately 350 employees. Under the long-term supply
agreement, TriRx will continue to provide Elanco with reliable
delivery of its products.
James Scandura, COO of TriRx,
said, "The Speke facility is located close to Liverpool, UK, which is strategically
important for TriRx. It is the fifth location for us and takes us
to two manufacturing facilities in North
America and two in Europe.
It also adds API and biological capabilities to our portfolio, and
further capacity capable of manufacturing both animal health and
human health products."
TriRx officially took ownership of the Speke facility on
February 1st, 2022 with a formal
celebration event scheduled for February
8th, attended by Maria Eagle,
UK Member of Parliament for Garston and Halewood, as well as other
local dignitaries, key customers, pharmaceutical executives,
personnel from TriRx and Elanco, and local community members.
Dave Urbanek, Executive Vice
President of Manufacturing & Quality at Elanco Animal Health,
said, "Since the sale of the Shawnee facilty to TriRx in August last year,
our partnership has been very successful, and we are delighted to
complete this next step with the Speke facilty sale and continue
our long-term strategic supply agreement with a major supplier that
shares our vision."
About TriRx
TriRx Pharmaceutical Services is a global contract
development and manufacturing organization (CDMO) serving
biopharmaceutical and animal health markets. Headquartered
approximately 50 miles outside of New
York City in Norwalk,
Connecticut, TriRx operates facilities in multiple regions
providing state-of-the-art laboratory, manufacturing, packaging,
warehousing, and technical service capabilities. Founded and led by
a team of pharmaceutical industry executives, who have served as
both contract service providers and outsourcing customers, TriRx
has a profound and multifaceted understanding of client needs. It
has the knowledge and commitment to deliver an exceptional
experience on every project, consistently meeting or exceeding
quality standards, regulatory requirements, on-time-in-full (OTIF)
delivery, and all other customer requirements and expectations.
Learn more at trirx.com.
For further information
TriRx Media Contact:
Nick
Cirignano
Senior Vice President
TriRx Pharmaceutical Services Inc.
Telephone: +1 917 767 3614
Email: nlcirignano@trirx.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/trirx-completes-acquisition-of-elanco-manufacturing-facility-in-speke-united-kingdom-301477871.html
SOURCE TriRx Pharmaceutical Services